CompanyGraph
Qianjiang Yongan Pharmaceutical Co. Ltd.
002365 · SZSE · China
chinataurine.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 13.99: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.69%Below 5Y avg (0.92%)
Annual Rate
CNY 0.10Paid annual
Payout Ratio
83.6%Moderate
Last Ex-Dividend
Jun 11, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.58BCNY679.56M · vs all stocks (USD)
Trailing P/E
129.58xRevenue (TTM)
847.91MCNY125.75M · vs all stocks (USD)
Profit Margin
4.08%Beta
0.2850xvs all stocks
52-Week Change
-27.75%vs all stocks
Market Capitalization
4.58BCNY679.56M · vs all stocks (USD)
Enterprise Value
3.21BCNY475.81M · vs all stocks (USD)
Trailing P/E
129.58xForward P/E
18.96xPrice to Sales (TTM)
5.40xPrice to Book (MRQ)
2.25xEnterprise to Revenue
3.78xEnterprise to EBITDA
24.33xGross Margin
20.23%Profit Margin
4.08%Operating Margin
4.55%Return on Assets (TTM)
0.40%Return on Equity (TTM)
1.09%Revenue (TTM)
847.91MCNY125.75M · vs all stocks (USD)
Revenue per Share (TTM)
2.93CNYUpdated Aug 19, 2026Quarterly Revenue Growth
37.80%Gross Profit (TTM)
162.18MCNY24.05M · vs all stocks (USD)
EBITDA (TTM)
144.96MCNY21.50M · vs all stocks (USD)
Net Income (TTM)
34.60MCNY5.13M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
7.18%Operating Cash Flow (TTM)
112.95MCNY16.75M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
33.05MCNY4.90M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1000CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.69%vs all stocks
5-Year Average Dividend Yield
0.92%vs all stocks
Payout Ratio
83.61%Minority Interest (Equity)
-5.07MCNYFY2025 · Dec 31, 2025Revenue
783.17MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
650.68MCNYFY2025 · Dec 31, 2025Gross Profit
132.48MCNYFY2025 · Dec 31, 2025Operating Income
-2.72MCNY-403.40K · vs all stocks (USD)
Pre-tax Income
9.88MCNYFY2025 · Dec 31, 2025Income Tax Expense
2.69MCNYFY2025 · Dec 31, 2025Net Income
7.19MCNYFY2025 · Dec 31, 2025EBIT
10.82MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
144.96MCNYFY2025 · Dec 31, 2025Research & Development
30.88MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
45.68MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.03MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.36MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
941.50KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0777CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0777CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
289.49MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
289.49MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
7.19MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
15.30MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
40.52MCNYFY2025 · Dec 31, 2025Free Cash Flow
-21.39MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
230.59MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
7.19MCNYFY2025 · Dec 31, 2025Other Non-cash Items
941.50KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
39.58MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.19MCNYFY2025 · Dec 31, 2025Capital Expenditures
-61.91MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.14BCNYFY2025 · Dec 31, 2025Sale of Investments
1.09BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-120.05MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
15.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-54.50MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-29.88MCNYFY2025 · Dec 31, 2025Other Financing Charges
-40.79MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-110.17MCNYFY2025 · Dec 31, 2025Shares Outstanding
294.68MSharesUpdated Aug 19, 2026Float Shares
207.60MSharesUpdated Aug 19, 2026% Held by Insiders
29.68%vs all stocks
% Held by Institutions
1.32%vs all stocks
Total Cash (MRQ)
875.98MCNY129.91M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.03CNYUpdated Aug 19, 2026Total Debt (MRQ)
745.18KCNY110.51K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0004xCurrent Ratio (MRQ)
5.95xBook Value per Share (MRQ)
6.90CNYUpdated Aug 19, 2026Total Assets
2.20BCNY326.36M · vs all stocks (USD)
Total Current Assets
1.15BCNYFY2025 · Dec 31, 2025Total Liabilities
218.72MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.05BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
14.79MCNYFY2025 · Dec 31, 2025Total Current Liabilities
203.94MCNYFY2025 · Dec 31, 2025Cash
229.36MCNYFY2025 · Dec 31, 2025Cash Equivalents
1.23MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
230.59MCNYFY2025 · Dec 31, 2025Other Short-term Investments
687.89MCNYFY2025 · Dec 31, 2025Accounts Receivable
116.84MCNYFY2025 · Dec 31, 2025Inventory
90.89MCNYFY2025 · Dec 31, 2025Accounts Payable
115.57MCNYFY2025 · Dec 31, 2025Short-term Debt
750.00KCNYFY2025 · Dec 31, 2025Other Current Liabilities
11.58MCNYFY2025 · Dec 31, 2025Common Stock (Book)
294.68MCNYFY2025 · Dec 31, 2025Retained Earnings
830.81MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.98BCNY293.92M · vs all stocks (USD)
Treasury Stock
40.48MCNYFY2025 · Dec 31, 202552-Week Low
9.82CNYUpdated Aug 19, 202652-Week High
20.54CNYUpdated Aug 19, 202652-Week Change
-27.75%vs all stocks
Beta
0.2850xvs all stocks
50-Day MA
11.76CNYUpdated Aug 19, 2026200-Day MA
13.87CNYUpdated Aug 19, 2026Avg 10-Day Volume
29.64MSharesUpdated Aug 19, 2026Avg 30-Day Volume
26.40MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.1200CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 13.99: safe zoneNotable
Altman Z-Score: 13.99
High earnings qualityNotable
Earnings Quality Score: 0.77
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai ShenQi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xiangxue Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Supriya Lifescience Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Gyre Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Henan Taloph Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BridgeBio Oncology Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vishee Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Newland Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Lisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule